Previous close | 3.1000 |
Open | 3.1500 |
Bid | 3.0100 x 700 |
Ask | 3.0800 x 1000 |
Day's range | 3.0300 - 3.1600 |
52-week range | 0.5000 - 3.9300 |
Volume | |
Avg. volume | 2,364,916 |
Market cap | 459.492M |
Beta (5Y monthly) | 1.81 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5500 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.75 |
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") and the Medicare Ambulatory Surgical Center ("ASC") payment system (the "Proposed Rule") as a qualifying product effective April 1, 2025. This Proposed Rule for payment within hospital outp
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.